RxDoctor Payments Data

Marc Abrams

Ophthalmology · Cleveland, OHNPI 1598763393

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, AbbVie. That places this record below the midpoint for ophthalmology clinicians in OH, where the typical reported total is $1,115.

$13in general payments, 2019–2025

Across 1 payment — averaging $13.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13
$222,741in research payments, 2019–2025

Across 22 payments — averaging $10,125 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$116K
  • Novartis$65K
  • Ocular Therapeutix, Inc.$23K
  • Kala Pharmaceuticals, Inc.$13K
  • Osmotica Pharmaceutical Corp.$5K

What the payments were for

  • Food & beverage$13100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie1$13

How this compares

$13 in reported general payments places this provider in the 0th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$144,220
Medicare patients
430
Services billed
2,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost105$56,957
RhopressaNetarsudil Mesylate40$14,677
Alphagan PBrimonidine Tartrate28$14,023
VyzultaLatanoprostene Bunod30$12,048
Timolol Maleate139$10,240
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$9,345
CombiganBrimonidine Tartrate/Timolol30$9,192
Travoprost81$8,477
SimbrinzaBrinzolamide/Brimonidine Tart37$7,498
Brimonidine Tartrate129$5,158
Latanoprost517$4,990
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat178$2,648
Dorzolamide Hcl133$2,441
Prednisolone Acetate55$2,266
Acetazolamide ErAcetazolamide12$2,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$13$80,171163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →